Has Christopher Latanich, MD received payments from drug or device companies?

Yes. Drug and device makers reported $128,035 in general payments to Christopher Latanich, MD across 148 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Latanich, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Latanich, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Latanich, MD

Cardiovascular Disease · Duluth, MNNPI 1336434778

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $87,950 of the $128,035 with a category attached, or 68.7%. Boston Scientific accounts for 89.5% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $86,887, more than ten times the $5,166 reported in 2019. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$128,035in general payments, 2019–2025

Across 148 payments — averaging $865.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$115K
Medtronic$6K
Biotronik Inc.$4K
Philips North America LLC$2K
ZOLL Respicardia, Inc.$562
Biosense Webster, Inc.$345
plus $386 from 2 others

$24,613in research payments, 2019–2025

Across 16 payments — averaging $1538.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$25K

What the payments were for

Consulting fees$24,90619%
Speaking & faculty fees$87,95069%
Travel & lodging$10,2168%
Food & beverage$4,5434%
Education$4200%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	99	$114,585
Medtronic(2 entities)	11	$5,956
Biotronik Inc.	12	$4,282
Philips North America LLC	8	$1,919
ZOLL Respicardia, Inc.	2	$562
Biosense Webster, Inc.	6	$345
Atricure, Inc.	8	$316
Angiodynamics, Inc.	2	$70

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,035 in reported general payments places this provider in the 90th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$157,504

Medicare patients

674

Services billed

1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XareltoRivaroxaban	32	$42,448
EliquisApixaban	51	$40,718
Flecainide Acetate	98	$3,362
Dofetilide	11	$2,475
Amiodarone Hcl	64	$959
Mexiletine Hcl	13	$592
Metoprolol Succinate	44	$362
SotalolSotalol Hcl	25	$351
Metoprolol Tartrate	27	$137

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Duluth

Graham LohrmannDuluth$47K
Jeffrey ChambersMinneapolis$3.2M
Srijoy MahapatraRochester$1.2M
Markus MeyerMinneapolis$786K
Robert SchwartzMinneapolis$502K
Robert VantasselMinneapolis$493K
Charanjit RihalRochester$478K
Amir LermanRochester$465K
Nedaa SkeikMinneapolis$453K
Joao CavalcanteMinneapolis$384K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →